Last reviewed · How we verify
Liraglutide treatment 12 weeks — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Liraglutide treatment 12 weeks (Liraglutide treatment 12 weeks) — Amsterdam UMC, location VUmc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Liraglutide treatment 12 weeks TARGET | Liraglutide treatment 12 weeks | Amsterdam UMC, location VUmc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Liraglutide treatment 12 weeks CI watch — RSS
- Liraglutide treatment 12 weeks CI watch — Atom
- Liraglutide treatment 12 weeks CI watch — JSON
- Liraglutide treatment 12 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Liraglutide treatment 12 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/liraglutide-treatment-12-weeks. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab